Recently, issues were raised concerning the results of a clinical trial for the blood thinning drug Xarelto. It was discovered that a medical device used during the study was faulty and was later recalled. The effect this may have had on the study is especially concerning as more than 13 million prescriptions have been written for the drug nationwide.… Read More


An Indiana woman was awarded $12.5 million dollars against Johnson & Johnson’s Ethicon unit in damages for the injuries she suffered from their ProLift transvaginal mesh implant. The Court of Common Pleas jury awarded $5.5 million dollars in compensatory damages and added $7 million dollars in punitive damages to punish Johnson & Johnson for recklessly marketing the device.… Read More


On Tuesday, the Food and Drug Administration (FDA) announced it is investigating a possible increased risk for heart failure associated with the diabetes drug Saxagliptin, manufactured by Bristol-Myers Squibb and AstraZeneca and marketed as Onglyza and Kombiglyze XR. The FDA has requested full data from the results of a recent clinical trial assessing the cardiovascular safety and efficacy of many current medications used to treat type 2 diabetes, including Saxagliptin (SAVOR trial). The FDA intends to further investigate the 27% increased risk of hospitalization for heart failure among patients taking the Saxagliptin reported in the study. The findings were first reported in August of 2013 at the European Society of Cardiology meeting and subsequently published in the New England Journal of Medicine.… Read More


Posted by Marilyn McGoldrick on Feb 3, 2014 3:32:00 PM On Friday, the federal judge overseeing the Ethicon transvaginal mesh (TVM) litigation ruled that Johnson & Johnson (J&J) and its subsidiary, Ethicon, will not be allowed to introduce evidence that the FDA had previously approved surgical sutures made out of the same polypropylene used in Gynecare… Read More


The first federal MDL Bellwether trial in the Actos litigation (MDL 2299) began yesterday in Lafayette, Louisiana before the Honorable Rebecca Doherty. The plaintiff is Terrance Allen, a New York man who was prescribed the diabetes drug Actos from 2004 until 2011 when he was diagnosed with bladder cancer. Allen’s opening statement asserts that the evidence will show that Takeda had information about Actos causing bladder cancer for over 10 years and withheld this information from doctors and patients. Actos also raises the risk of heart disease, although that is not at issue in this trial.… Read More


Today there are multiple news reports of great interest to people suffering from defective hip replacements: Johnson & Johnson’s subsidiary DePuy Orthopaedics has agreed to a tentative settlement of over 4 billion dollars to resolve thousands of DePuy Articular Surface Replacement (ASR) hip implant lawsuits. This would make it the largest recorded settlement for a defective medical device in US history.… Read More


Men of all ages who are currently using or considering testosterone therapy for increased energy and libido should be aware of new research published in the Journal of the American Association of Medicine (JAMA). According to the study of 8000 men in the Veterans Administration health system, there may be a link between testosterone therapy and a greater risk of heart attacks, strokes, and even death.… Read More


A second DePuy ASR hip implant case scheduled for trial this month has been resolved, according to court records. The lawsuit, MacDonald et al v. DePuy Orthopaedics Inc. et al, was filed in the Bergen County division of the New Jersey Superior Court and was scheduled to go to trial on October 21, 2013 before the Honorable Brian R. Martinotti. There are few details about the settlement available at this time and, as with prior Depuy hip settlements, the terms will likely remain confidential.

The lawsuit, MacDonald et al v. DePuy Orthopaedics Inc. et al, was filed in the Bergen County division of the New Jersey Superior Court and was scheduled to go to trial on October 21, 2013 before the Honorable Brian R. Martinotti. There are few details about the settlement available at this time and, as with prior Depuy hip settlements, the terms will likely remain confidential.… Read More


Posted by Thornton Law Firm LLP on Sep 25, 2013 4:30:00 AM Dr. Frances Oldham Kelsey Released in Germany in 1957 as an all-purpose sedative, but later widely used as a preventative treatment for “morning sickness,” Thalidomide caused an estimated 10,000 – 20,000 severe birth defects worldwide. The injuries associated with a mother’s ingesting Thalidomide… Read More